InMed Pharmaceuticals (INM) Non Operating Income (2023 - 2024)
InMed Pharmaceuticals (INM) posted quarterly Non Operating Income of $528120.0 for Q2 2024, up 255.5% year-over-year from $148559.0 in Q3 2023, and up 334.82% quarter-over-quarter from $121458.0 in Q1 2024.
InMed Pharmaceuticals (INM) Non Operating Income (2023 - 2024) Analysis & Trends
InMed Pharmaceuticals' Non Operating Income history runs 2 years deep, the most recent figure standing at $528120.0 for Q2 2024.
- In Q2 2024, Non Operating Income rose 255.5% year-over-year to $528120.0; the TTM figure through Jun 2024 stood at $953634.0 (changed N/A YoY), while the FY2024 annual figure was $527901.0, up 7.2% from the prior year.
- Non Operating Income for Q2 2024 stood at $528120.0, up from $121458.0 in the prior quarter.
- The five-year high for Non Operating Income was $528120.0 in Q2 2024, with the low at $121458.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.52 Mn | 1.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 528,120.00 |
| Mar 31, 2024 | 121,458.00 |
| Jun 30, 2023 | 148,559.00 |
| Mar 31, 2023 | 155,497.00 |